Pandion Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Pandion Therapeutics, Inc. | PAND - NASDAQ |
$16.00-$18.00 | $18.00 | $27.00 | 7.5 million | 7/17/2020 |
| Goldman Sachs, Morgan Stanley, SVB Leerink, BMO Capital Markets | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-06-26 Terms Added 2020-07-13 Terms Changed 2020-07-16 | ||||||
Pandion Therapeutics, Inc. Quote & Chart - Click for current quote - PAND
IPO Boutique aggregates information on public companies and private companies, such as "PAND" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Pandion Therapeutics, Inc. (adapted from Pandion Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PAND" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.